Titleist Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Titleist Asset Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$385K	Sell	7,100 -1,250	-15%	-$56.2K	0.02%	329
2026 Q2	$351K	Hold	8,350	–	–	0.02%	328
2026 Q1	$221K	Hold	8,350	–	–	0.02%	383
2025 Q4	$242K	Hold	8,350	–	–	0.02%	347
2025 Q3	$232K	Sell	8,350 -450	-5%	-$11.4K	0.02%	289
2025 Q2	$214K	Buy	+8,800	New	+$193K	0.02%	300
2025 Q1	–	Sell	-11,975	Closed	-$282K	–	299
2024 Q4	$282K	Sell	11,975 -4,600	-28%	-$113K	0.03%	259
2024 Q3	$424K	Sell	16,575 -300	-2%	-$7.64K	0.06%	189
2024 Q2	$396K	Hold	16,875	–	–	0.06%	187
2024 Q1	$485K	Buy	16,875 +10,275	+156%	+$309K	0.09%	154
2023 Q4	$217K	Buy	+6,600	New	+$179K	0.04%	206

Other funds holding ARKG

MFPI

Midwest Financial Partners Investments St. Cloud, Minnesota $260M AUM 10.89% 1-Year Est. Return

CFIM

Client First Investment Management West Bend, Wisconsin $210M AUM 50.85% 1-Year Est. Return

PRTG

Post Resch Tallon Group Pittsford, New York $146M AUM 18.19% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

MHR

Matthew Hamilton Rosenberg $558M AUM 12.28% 1-Year Est. Return

AAG

Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Titleist Asset Management's ARKG Position: Q3 2026 in Review

Titleist Asset Management reduced its ARK Genomic Revolution ETF (ARKG) stake by 15% in Q3 2026, selling an estimated $56.2K and leaving 7,100 shares worth $385K. The position accounts for 0.02% of the portfolio, ranked #329.

Titleist Asset Management first reported a position in ARKG in Q4 2023 and has held it in 11 quarters since. The position peaked at $485K in Q1 2024. 8 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.

Titleist Asset Management held 7,100 shares of ARK Genomic Revolution ETF worth $385K as of Q3 2026.
Titleist Asset Management sold 1,250 ARK Genomic Revolution ETF shares in Q3 2026, an estimated $56.2K.
ARK Genomic Revolution ETF made up 0.02% of Titleist Asset Management's portfolio in Q3 2026, its #329 holding.
Titleist Asset Management first reported a position in ARK Genomic Revolution ETF in Q4 2023 and has held it in 11 quarters since.
Titleist Asset Management's ARK Genomic Revolution ETF position peaked at $485K in Q1 2024.
8 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.

Based on Titleist Asset Management's 13F filing for Q3 2026, filed 8 Oct 2026.